PARP inhibitor Olaparib increases the sensitization to radiotherapy in FaDu cells
Open Access
- 19 January 2020
- journal article
- research article
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 24 (4) , 2444-2450
Abstract
Radioresistance causes a major problem for improvement of outcomes of patients treated with radiation. Targeting for DNA repair deficient mechanisms is a hallmark of sensitization to resistance. We tested whether Olaparib, a (poly) ADP‐ribose polymerase (PARP) inhibitor, can sensitize the radioresistant FaDu cells to radiotherapy. Radioresistant FaDu cells, called FaDu‐RR cells, were used as the radioresistant hypopharyngeal cancer models. The expression of PARP1 was detected in both FaDu and FaDu‐RR cells. The role of Olaparib in radiosensitization was analysed with several assays including clonogenic cell survival, cell proliferation and cell cycle, and radioresistant xenograft. High expression of PARP1 had a significant effect on enhancing radioresistance in FaDu‐RR cells compared with FaDu cells. After treatment of Olaparib, FaDu‐RR cells showed significantly less and smaller surviving colonies, lower proliferation ability and G2/M arrest than those in the group without treatment. Moreover, Olaparib significantly reduced growth of tumours in FaDu‐RR cell xenografts treated with ionizing radiation. Olaparib can significantly inhibit PARP1 expression and consequently has significant effects on radiosensitization in FaDu‐RR cells. These results indicate that Olaparib may help individualize treatment and improve their outcomes of hypopharyngeal cancer patients treated with radiation.Keywords
This publication has 33 references indexed in Scilit:
- Structural Basis for DNA Damage–Dependent Poly(ADP-ribosyl)ation by Human PARP-1Science, 2012
- Apurinic/apyrimidinic (AP) site recognition by the 5′-dRP/AP lyase in poly(ADP-ribose) polymerase-1 (PARP-1)Proceedings of the National Academy of Sciences, 2010
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trialThe Lancet, 2010
- Targeting EGFR Induced Oxidative Stress by PARP1 Inhibition in Glioblastoma TherapyPLOS ONE, 2010
- Activation of PARP-1 in response to bleomycin depends on the Ku antigen and protein phosphatase 5Oncogene, 2010
- The DNA-damage response in human biology and diseaseNature, 2009
- PARP is activated at stalled forks to mediate Mre11‐dependent replication restart and recombinationThe EMBO Journal, 2009
- Squamous cell carcinoma of the hypopharynx: Single-institution outcome analysis of a large cohort of patients treated with primary non-surgical approachesActa Oncologica, 2009
- Early steps in the DNA base excision/single-strand interruption repair pathway in mammalian cellsCell Research, 2008
- Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymeraseNature, 2005